|
Market Closed -
London S.E.
12:35:06 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 1,731.00 GBX | +0.41% |
|
+3.28% | +11.68% |
| 10-28 | US estrogen supply crunch widens as women seek alternatives to scarce patches | RE |
| 10-20 | Hikma Pharmaceuticals PLC - Special Call |
Company Valuation: Hikma Pharmaceuticals PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,954 | 4,118 | 5,038 | 5,533 | 4,620 | 4,846 | - | - |
| Change | - | -40.78% | 22.33% | 9.82% | -16.5% | 4.89% | - | - |
| Enterprise Value (EV) 1 | 7,374 | 5,131 | 6,014 | 6,651 | 6,007 | 6,330 | 6,156 | 5,949 |
| Change | - | -30.41% | 17.2% | 10.59% | -9.68% | 5.38% | -2.75% | -3.37% |
| P/E | 16.6x | 22.4x | 26.8x | 15.5x | 11.5x | 12.6x | 11.2x | 10.2x |
| PBR | 2.84x | 1.93x | 2.29x | 2.39x | 1.77x | 1.78x | 1.62x | 1.48x |
| PEG | - | -0.4x | 16x | 0.2x | 0.9x | 7.71x | 0.9x | 1.03x |
| Capitalization / Revenue | 2.72x | 1.64x | 1.75x | 1.77x | 1.38x | 1.4x | 1.35x | 1.28x |
| EV / Revenue | 2.89x | 2.04x | 2.09x | 2.13x | 1.79x | 1.83x | 1.71x | 1.58x |
| EV / EBITDA | 10.1x | 7.39x | 7.42x | 8.07x | 7.04x | 7.35x | 6.76x | 6.19x |
| EV / EBIT | 11.7x | 8.61x | 8.51x | 9.25x | 8.11x | 8.83x | 8.11x | 7.27x |
| EV / FCF | 15x | 16.8x | 14.9x | 20.2x | 50.5x | 17.5x | 14.8x | 12.5x |
| FCF Yield | 6.69% | 5.94% | 6.72% | 4.95% | 1.98% | 5.72% | 6.76% | 8.01% |
| Dividend per Share 2 | 0.54 | 0.56 | 0.72 | 0.8 | 0.84 | 0.8639 | 0.9159 | 0.9917 |
| Rate of return | 1.8% | 2.99% | 3.16% | 3.21% | 4.03% | 3.73% | 3.95% | 4.28% |
| EPS 2 | 1.807 | 0.836 | 0.85 | 1.61 | 1.81 | 1.84 | 2.064 | 2.268 |
| Distribution rate | 29.9% | 67% | 84.7% | 49.7% | 46.4% | 47% | 44.4% | 43.7% |
| Net sales 1 | 2,553 | 2,517 | 2,875 | 3,127 | 3,349 | 3,459 | 3,600 | 3,772 |
| EBITDA 1 | 727 | 694 | 811 | 824 | 853 | 860.8 | 910.8 | 961.5 |
| EBIT 1 | 632 | 596 | 707 | 719 | 741 | 717.1 | 759.1 | 818.4 |
| Net income 1 | 421 | 188 | 190 | 359 | 402 | 412.2 | 453.4 | 497.8 |
| Net Debt 1 | 420 | 1,013 | 976 | 1,118 | 1,387 | 1,485 | 1,310 | 1,103 |
| Reference price 2 | 30.05 | 18.70 | 22.79 | 24.95 | 20.86 | 23.19 | 23.19 | 23.19 |
| Nbr of stocks (in thousands) | 231,442 | 220,230 | 221,080 | 221,748 | 221,452 | 208,950 | - | - |
| Announcement Date | 2/24/22 | 2/23/23 | 2/22/24 | 2/26/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 12.61x | 1.83x | 7.35x | 3.73% | 4.85B | |
| 41.54x | 14.06x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 38.61x | 8.62x | 17.83x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 109.15x | 6.06x | 25.73x | 2.28% | 369B | |
| 23.19x | 5.97x | 14.41x | 2.71% | 307B | |
| 24.47x | 4.9x | 13.63x | 1.77% | 290B | |
| 29.56x | 7.53x | 13.48x | 2.16% | 252B | |
| -49.1x | 7.47x | 29.35x | 1.93% | 212B | |
| Average | 29.18x | 6.84x | 18.49x | 2.18% | 426.68B | |
| Weighted average by Cap. | 37.26x | 8.83x | 21.95x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- HIK Stock
- Valuation Hikma Pharmaceuticals PLC
Select your edition
All financial news and data tailored to specific country editions
